Detalles de la búsqueda
1.
Trial of Upadacitinib and Adalimumab for Psoriatic Arthritis.
N Engl J Med
; 384(13): 1227-1239, 2021 04 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-33789011
2.
Upadacitinib for psoriatic arthritis refractory to biologics: SELECT-PsA 2.
Ann Rheum Dis
; 80(3): 312-320, 2021 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-33272960
3.
Use of Nonpalliative Medications Following Burdensome Health Care Transitions in Hospice Patients: A Matched Cohort Analysis.
Med Care
; 57(1): 13-20, 2019 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-30363022
4.
Older Medicare Beneficiaries Frequently Continue Medications with Limited Benefit Following Hospice Admission.
J Gen Intern Med
; 34(10): 2029-2037, 2019 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-31346909
5.
Real-World Use and Effectiveness Outcomes in Patients with Rheumatoid Arthritis Treated with Upadacitinib: An Analysis from the CorEvitas Registry.
Rheumatol Ther
; 11(2): 363-380, 2024 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-38345715
6.
Real-World Treatment and Care Patterns in Patients With Rheumatoid Arthritis Initiating First-Line Tumor Necrosis Factor Inhibitor Therapy in the United States.
ACR Open Rheumatol
; 6(4): 179-188, 2024 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-38221639
7.
Wearable activity tracker study exploring rheumatoid arthritis patients' disease activity using patient-reported outcome measures, clinical measures, and biometric sensor data (the wear study).
Contemp Clin Trials Commun
; 38: 101272, 2024 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-38444876
8.
One-Year Medication Adherence and Persistence in Rheumatoid Arthritis in Clinical Practice: A Retrospective Analysis of Upadacitinib, Adalimumab, Baricitinib, and Tofacitinib.
Adv Ther
; 40(10): 4493-4503, 2023 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-37542646
9.
Clinical and Economic Benefit of Achieving Disease Control in Psoriatic Arthritis and Ankylosing Spondylitis: A Retrospective Analysis from the OM1 Registry.
Rheumatol Ther
; 10(1): 187-199, 2023 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-36333490
10.
A Real-World Effectiveness Study Using a Mobile Application to Evaluate Early Outcomes with Upadacitinib in Rheumatoid Arthritis.
Rheumatol Ther
; 10(6): 1519-1533, 2023 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-37728861
11.
Routine Assessment of Patient Index Data 3 (RAPID3) in Patients with Rheumatoid Arthritis Treated with Long-Term Upadacitinib Therapy in Five Randomized Controlled Trials.
Rheumatol Ther
; 9(6): 1517-1529, 2022 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-36125701
12.
Experiences and Treatment Preferences in Patients With Psoriatic Arthritis: A Cross-Sectional Study in the ArthritisPower Registry.
Rheumatol Ther
; 9(2): 735-751, 2022 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-35279798
13.
Effect of upadacitinib on reducing pain in patients with active psoriatic arthritis or ankylosing spondylitis: post hoc analysis of three randomised clinical trials.
RMD Open
; 8(1)2022 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-35332058
14.
Site-specific resolution of enthesitis in patients with axial spondyloarthritis treated with tumor necrosis factor inhibitors.
Arthritis Res Ther
; 23(1): 165, 2021 06 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-34107999
15.
Patient-Reported Outcomes in Psoriatic Arthritis Patients with an Inadequate Response to Biologic Disease-Modifying Antirheumatic Drugs: SELECT-PsA 2.
Rheumatol Ther
; 8(4): 1827-1844, 2021 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-34661885
16.
Upadacitinib in patients with psoriatic arthritis and an inadequate response to non-biological therapy: 56-week data from the phase 3 SELECT-PsA 1 study.
RMD Open
; 7(3)2021 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-34663636
17.
Improvement in Patient-Reported Outcomes in Patients with Psoriatic Arthritis Treated with Upadacitinib Versus Placebo or Adalimumab: Results from SELECT-PsA 1.
Rheumatol Ther
; 8(4): 1789-1808, 2021 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-34636026
18.
Upadacitinib in Patients with Psoriatic Arthritis and Inadequate Response to Biologics: 56-Week Data from the Randomized Controlled Phase 3 SELECT-PsA 2 Study.
Rheumatol Ther
; 8(2): 903-919, 2021 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-33913086
19.
Longterm, Real-world Safety of Adalimumab in Rheumatoid Arthritis: Analysis of a Prospective US-based Registry.
J Rheumatol
; 47(7): 959-967, 2020 07 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-31371657
20.
Risk of Developing Additional Immune-Mediated Manifestations: A Retrospective Matched Cohort Study.
Adv Ther
; 36(7): 1672-1683, 2019 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-31102202